Abstract
Anaphylaxis is a severe, life-threatening systemic allergic reaction that requires immediate treatment with intramuscular epinephrine. Despite clear clinical guidelines, "epinephrine hesitancy" remains a significant barrier to care. This population-based study in South Korea investigated the disparity in epinephrine administration between pediatric and adult patients in Emergency Departments (ED). The findings reveal a significant underutilization of epinephrine in children, with usage rates decreasing as patient age decreases.
Introduction
Anaphylaxis requires prompt intervention to prevent fatal outcomes. While intramuscular epinephrine is universally recognized as the first-line treatment, healthcare providers often exhibit reluctance in its administration. Previous research suggested that children might receive epinephrine less frequently than adults, but large-scale, population-based evidence was needed to quantify this gap. This study aims to determine if age is a primary driver of treatment underuse in the ED and to identify potential barriers to optimal care for younger victims.
Methods
A retrospective cohort study was conducted using the National Sample Cohort of South Korea (NHIS-NSC) from 2004 to 2013. This dataset includes diagnostic codes (ICD-10), prescription records, and demographic data for approximately 1 million randomly sampled individuals from the entire Korean population.
The researchers utilized multivariable logistic regression to adjust for confounding factors, including:
- Demographics: Age, sex, and household income (socioeconomic status).
- Clinical History: Prior history of anaphylaxis or cardiovascular disease.
- Hospital Characteristics: Bed count and geographic setting (urban vs. rural).
A sensitivity analysis was also performed, excluding patients with a known history of anaphylaxis to account for potential pre-hospital use of personal epinephrine autoinjectors.
Results
The study identified a stark contrast in treatment patterns between pediatric and adult populations:
- Epinephrine Usage Rates: Only 24% of pediatric patients received epinephrine in the ED, compared to 36.9% of adults ($P = 0.001$).
- Age-Dependent Odds: Using the 19–65 age group as a baseline, the likelihood of receiving epinephrine decreased significantly as age decreased:
- Children < 7 years: 66% less likely to receive treatment (OR 0.34).
- Children 7–12 years: OR 0.56.
- Adolescents 13–18 years: OR 0.79.
- Systemic Steroids: Pediatric patients were also less likely to receive systemic steroids, reinforcing the trend of under-recognition or under-treatment of anaphylaxis in children.
- ICU Admissions: Interestingly, 0% of pediatric patients in the cohort required ICU admission, compared to 5.4% of adults. This may reflect differences in physiological resilience or a lower average severity in the pediatric cases captured in the claims data.
Discussion
The "Age Gradient" of care observed suggests a systemic reluctance to administer epinephrine to younger children. Several factors may contribute to this disparity:
- Diagnostic Challenges: Identifying anaphylaxis in infants and young children (under 7) is inherently difficult. Symptoms like crying or regurgitation can mask allergic reactions, and young children cannot articulate their distress.
- Symptom Presentation: Pediatric anaphylaxis often presents with respiratory symptoms, whereas adults more frequently exhibit cardiovascular instability (e.g., hypotension). Clinicians accustomed to "classic" adult presentations may miss the diagnosis in children.
- The Steroid Paradox: The lower rates of both epinephrine and steroid use in children point toward a general under-recognition of the severity of allergic reactions in pediatric patients.
Conclusion
This study highlights a critical gap in the emergency management of pediatric anaphylaxis. The significant underuse of epinephrine, particularly in children under seven, underscores the need for standardized, pediatric-specific protocols in Emergency Departments. Future efforts should focus on clinician education and the implementation of clear guidelines to ensure that all anaphylaxis victims, regardless of age, receive life-saving treatment promptly.
Summary updated